Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles A Butts

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Clinical Colorectal Cancer|August 16, 2005
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II studyChris J Twelves, Charles A Butts, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2021
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 TrialConor E Steuer, Opeyemi A Jegede, Suzanne E Dahlberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10Charles A Butts, Keyue Ding, Lesley Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancerCharles A Butts, David Bodkin, Edward L Middleman, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Colorectal Cancer|August 16, 2005
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II studyChris J Twelves, Charles A Butts, Jim Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2021
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 TrialConor E Steuer, Opeyemi A Jegede, Suzanne E Dahlberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10Charles A Butts, Keyue Ding, Lesley Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancerCharles A Butts, David Bodkin, Edward L Middleman, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
Pageof 2